Cysteine — Benefits Deep Dive

An airway lining, the tissue studied in N-acetylcysteine research
An airway lining, the tissue studied in N-acetylcysteine (NAC) research

Cysteine is the only proteinogenic amino acid carrying a reactive thiol (–SH) group, and that single chemical feature places it at the center of an unusually broad swath of human physiology. It is the rate-limiting amino acid for glutathione — the most abundant intracellular antioxidant in the body. It is the source of every disulfide bond in keratin (hair, nails), insulin, antibodies, and the hundreds of secreted proteins whose structure depends on covalent S–S cross-linking. It is the soft-metal-binding ligand in metallothionein and the conjugating group on glutathione, accounting for almost all Phase II xenobiotic detoxification. And it is the substrate for the cysteine sulfinic acid pathway that produces taurine, the most abundant free amino acid in heart and brain. Four benefit pages below explore the conditions where Cysteine produces the largest clinical effect — glutathione restoration in aging and chronic disease, the N-acetylcysteine-driven lung-health applications from chronic obstructive pulmonary disease (COPD) to acetaminophen rescue, structural-protein support for hair and nail health, and the detoxification pathways that handle everything from heavy metals to industrial solvents to cigarette smoke.

Deep-Dive Articles

🛡️

Glutathione Synthesis

Cysteine as the rate-limiting amino acid for glutathione — the master intracellular antioxidant. The two-enzyme synthetic pathway (glutamate-cysteine ligase, glutathione synthetase), why cysteine specifically rate-limits, the 20-40% age-related decline in glutathione, and the small GlyNAC trials at Baylor College of Medicine (an open-label 2021 pilot in 8 older adults and a 2023 placebo-controlled trial in 24 older adults) that reported improved glutathione, oxidative-stress, mitochondrial, inflammation, insulin-resistance and physical-function measures with combined glycine + N-acetylcysteine supplementation. Plus the N-acetylcysteine vs free cysteine vs liposomal glutathione vs whey protein comparison.

Read the deep dive →
🫁

N-Acetylcysteine and Lung Health

N-acetylcysteine as a cysteine prodrug for pulmonary disease — mucolytic action through cleavage of mucin disulfide bonds, the IFIGENIA and PANTHER-IPF saga in idiopathic pulmonary fibrosis, the chronic obstructive pulmonary disease flare-up trials (BRONCUS at 600 mg/day found no fewer flare-ups; PANTHEON at 1,200 mg/day found fewer), the Rumack-Matthew acetaminophen overdose antidote protocol, plus bronchiectasis, cystic fibrosis, asthma cautions, and the rise and fall of N-acetylcysteine for contrast nephropathy.

Read the deep dive →
💇

Hair & Nails

Cysteine's disulfide bonds in keratin — the structural reason hair (14-18% cysteine by weight) and nails are strong. A hair supplement combining cystine, B vitamins and keratin and its reported use for telogen effluvium (diffuse hair shedding), brittle nail syndrome (onychoschizia), why biotin alone is not enough, the perming and chemical straightening chemistry that proves the disulfide-cysteine mechanism, and the broader nutritional stack (iron, zinc, vitamin D, protein) that supports the cysteine-keratin pathway.

Read the deep dive →
🧹

Detoxification

Cysteine in metallothionein for heavy-metal binding (cadmium, mercury, copper), Phase II glutathione-S-transferase conjugation and the mercapturate pathway, N-acetylcysteine for mercury chelation, a chelation protocol popular online, how N-acetylcysteine compares to drug chelators dimercaptosuccinic acid (DMSA) and dimercaptopropane sulfonate (DMPS), the sulfation pathway (3′-phosphoadenosine-5′-phosphosulfate (PAPS), sulfotransferases) for hormone and drug clearance, and when cysteine supplementation helps and when it does not.

Read the deep dive →

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why Cysteine Produces Effects Across Many Systems
  3. Research Papers: Glutathione Synthesis
  4. Research Papers: N-Acetylcysteine and Lung Health
  5. Research Papers: Hair and Nails
  6. Research Papers: Detoxification
  7. Research Papers: Cross-Cutting (Forms, Status, Safety)
  8. External Authoritative Resources
  9. Connections
  10. Featured Videos

Why Cysteine Produces Effects Across Many Systems

Cysteine's unusually broad biological footprint flows from four distinct molecular roles that no other amino acid combines. Each role maps to a category of clinical effect, and each is essential to a separate group of body systems — which is why cysteine deficiency or supplementation produces simultaneous effects in places that seem at first unrelated (skin, lungs, liver, brain, cardiovascular system).

  1. Rate-limiting precursor for glutathione — cysteine is the limiting amino acid in the synthesis of glutathione, the most abundant intracellular antioxidant in the body. Glutathione protects mitochondria, neurons, hepatocytes, and immune cells from oxidative damage; cofactors hundreds of Phase II detoxification enzymes; recycles oxidized Vitamin C and Vitamin E back to their reduced forms; and maintains the reduced state of critical protein thiols across thousands of enzymes. The glutathione-synthesis page explores how a deficit here ripples through aging, neurodegeneration, insulin resistance, and chronic inflammation.
  2. Only proteinogenic amino acid with a reactive thiol side chain — the –SH on the cysteine side chain is the only nucleophilic sulfur in the standard 20 amino acid set. This thiol forms covalent disulfide (S–S) bonds with other cysteine residues, which is the single mechanism that stabilizes the tertiary structure of secreted proteins. Insulin has three disulfide bonds. Antibodies have multiple inter-chain and intra-chain disulfide bonds. Every secreted hormone, enzyme, and antibody depends on cysteine cross-linking. The disulfide bond is also the structural feature that makes keratin keratin — see hair and nails.
  3. Soft-metal-binding ligand and electrophile conjugator — the cysteine thiol's polarizable sulfur preferentially binds soft metal cations (mercury, lead, cadmium, copper) and conjugates electrophilic xenobiotic intermediates. This is the molecular basis for metallothionein (a 20-cysteine cage that binds heavy metals) and for the glutathione-S-transferase Phase II detoxification system. The detoxification page walks through the metal-binding and Phase II conjugation chemistry in detail.
  4. Substrate for the cysteine sulfinic acid pathway producing taurine and sulfate — cysteine is oxidized in the liver by cysteine dioxygenase to cysteine sulfinic acid, which is then either decarboxylated to hypotaurine (and then to taurine, the most abundant free amino acid in heart and brain) or further oxidized to sulfate, which is then activated as PAPS, the universal sulfate donor used by all sulfotransferases. This is how cysteine fuels the sulfation arm of Phase II detoxification, the synthesis of glycosaminoglycans (proteoglycans, heparan sulfate, dermatan sulfate), and the production of taurine for the cardiovascular and central nervous systems.

The therapeutic complication is that cysteine is also unusually metabolically dangerous to accumulate. Free cysteine in plasma at supraphysiologic concentration is auto-oxidizing, can generate hydrogen peroxide, and can excitotoxically over-activate N-methyl-D-aspartate (NMDA) glutamate receptors. The body therefore maintains very low free cysteine and instead stores most of its sulfur-amino-acid pool as glutathione (in cells) and as cystine (in plasma). This is why the standard clinical supplemental form is N-acetylcysteine rather than free cysteine: N-acetylcysteine is stable in storage, well-absorbed orally, and rapidly deacetylated inside cells to release cysteine directly into the safer intracellular environment, bypassing the auto-oxidation problems of free cysteine in plasma.

The fourth deep-dive page explores how N-acetylcysteine's combination of mucolytic action and glutathione-restoration mechanism made it both the oldest mucolytic drug still in use and the definitive antidote for acetaminophen overdose — two clinical applications that look unrelated at first but flow from the same underlying thiol chemistry.

Back to Table of Contents

Research Papers: Glutathione Synthesis

  1. Kumar P et al. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and Translational Medicine. 11(3):e372. — PubMed PMID: 33783984
  2. Kumar P et al. (2023). Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. Journals of Gerontology, Series A: Biological Sciences and Medical Sciences. 78(1):75-89. — PubMed PMID: 35975308
  3. Sekhar RV et al. (2011). Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 34(1):162-7. — PubMed PMID: 20929994
  4. Sekhar RV et al. (2011). Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. American Journal of Clinical Nutrition. 94(3):847-53. — PubMed PMID: 21795440
  5. Lu SC (2013). Glutathione synthesis. Biochimica et Biophysica Acta. 1830(5):3143-53. — PubMed PMID: 22995213
  6. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007). N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Current Opinion in Pharmacology. 7(4):355-9. — PubMed PMID: 17602868
  7. Wu G et al. (2004). Glutathione metabolism and its implications for health. Journal of Nutrition. 134(3):489-92. — PubMed PMID: 14988435
  8. Bounous G (2000). Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Research. 20(6C):4785-92. — PubMed PMID: 11205219
  9. Richie JP Jr et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 54(2):251-63. — PubMed PMID: 24791752
  10. Sinha R et al. (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition. 72(1):105-111. — PubMed PMID: 28853742
  11. Forman HJ, Zhang H, Rinna A (2009). Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine. 30(1-2):1-12. — PubMed PMID: 18796312

The two GlyNAC (glycine plus N-acetylcysteine) trials are small. The 2021 study was an open-label pilot with no placebo: eight older adults took GlyNAC for 24 weeks, and the measured improvements declined after they stopped for 12 weeks. The 2023 trial was placebo-controlled: 24 older adults took either GlyNAC or an alanine placebo for 16 weeks. The GlyNAC group, and not the placebo group, showed better glutathione levels, oxidative stress, mitochondrial function, inflammation, insulin resistance, physical function (gait speed, strength) and blood pressure, and the supplement was well tolerated.

Back to Table of Contents

Research Papers: N-Acetylcysteine and Lung Health

  1. Decramer M et al. (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. The Lancet. 365(9470):1552-60. — PubMed PMID: 15866309 (Result: 523 people with chronic obstructive pulmonary disease took 600 mg a day or a placebo for 3 years; flare-ups per year did not differ, 1.25 vs 1.29, hazard ratio 0.99, and lung-function decline did not differ either.)
  2. Zheng JP et al. (2014). Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respiratory Medicine. 2(3):187-94. — PubMed PMID: 24621680 (Result: 1,006 people with moderate-to-severe chronic obstructive pulmonary disease in China took 600 mg twice a day (1,200 mg a day) or a placebo for 1 year; flare-ups were 1.16 vs 1.49 per patient-year, risk ratio 0.78.)
  3. Tse HN et al. (2013). High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 144(1):106-118. — PubMed PMID: 23348146
  4. Demedts M et al. (2005). High-dose acetylcysteine in idiopathic pulmonary fibrosis. New England Journal of Medicine. 353(21):2229-42. — PubMed PMID: 16306520 (Result: 600 mg three times a day added to prednisone and azathioprine for 1 year; vital capacity fell 0.18 liter less than with those two drugs alone, a 9% relative difference; deaths 9% vs 11%, not a significant difference.)
  5. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ et al. (2014). Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. New England Journal of Medicine. 370(22):2093-101. — PubMed PMID: 24836309 (Result: acetylcysteine alone vs placebo for 60 weeks; lung capacity (forced vital capacity) fell about the same, 0.18 vs 0.19 liter, with no difference in deaths or flare-ups.)
  6. Prescott LF et al. (1979). Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. British Medical Journal. 2(6198):1097-100. — PubMed PMID: 519312
  7. Rumack BH, Matthew H (1975). Acetaminophen poisoning and toxicity. Pediatrics. 55(6):871-6. — PubMed PMID: 1134886
  8. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH (1988). Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). New England Journal of Medicine. 319(24):1557-62. — PubMed PMID: 3059186
  9. Qi Q et al. (2019). Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respiratory Research. 20(1):73. — PubMed PMID: 30975143 (Result: 161 adults with bronchiectasis in China who had at least two flare-ups the year before took 600 mg twice a day for 12 months or usual on-demand care; flare-ups were 1.31 vs 1.98 per patient-year, and daily sputum volume was lower.)
  10. Sutherland ER, Crapo JD, Bowler RP (2006). N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease. 3(4):195-202. — PubMed PMID: 17361500 (Result: 8 trials, 2,214 people with chronic obstructive pulmonary disease; N-acetylcysteine halved the odds of having one or more flare-ups, odds ratio 0.49; the effect looked smaller in people using inhaled steroids.)
  11. Cai X et al. (2026). The efficacy of N-acetylcysteine in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis. PeerJ. 14:e21448. — PubMed PMID: 42473447

The chronic obstructive pulmonary disease (COPD) trials point in different directions. BRONCUS, at 600 mg a day, found no fewer flare-ups (exacerbations); PANTHEON, at 1,200 mg a day, found fewer. A 2026 meta-analysis pooled 14 randomized trials with 2,856 people with COPD: N-acetylcysteine was linked to about 13% fewer flare-ups (risk ratio 0.87). In its dose subgroups, doses of 600 mg a day or less were linked to fewer flare-ups (risk ratio 0.84), while doses above 600 mg a day did not reach statistical significance (risk ratio 0.88). It did not improve lung-function numbers (forced expiratory volume in one second and forced vital capacity), quality-of-life scores or measured glutathione, and side effects were no more common than in the control groups.

Back to Table of Contents

Research Papers: Hair and Nails

  1. Trüeb RM (2009). Oxidative stress in ageing of hair. International Journal of Trichology. 1(1):6-14. — PubMed PMID: 20805969
  2. Hochman LG, Scher RK, Meyerson MS (1993). Brittle nails: response to daily biotin supplementation. Cutis. 51(4):303-5. — PubMed PMID: 8477615
  3. Patel DP, Swink SM, Castelo-Soccio L (2017). A Review of the Use of Biotin for Hair Loss. Skin Appendage Disorders. 3(3):166-169. — PubMed PMID: 28879195
  4. Rushton DH (2002). Nutritional factors and hair loss. Clinical and Experimental Dermatology. 27(5):396-404. — PubMed PMID: 12190640
  5. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A (2019). The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatology and Therapy. 9(1):51-70. — PubMed PMID: 30547302
  6. Olsen EA, Reed KB, Cacchio PB, Caudill L (2010). Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. Journal of the American Academy of Dermatology. 63(6):991-9. — PubMed PMID: 20947203
  7. Petri H, Pierchalla P, Tronnier H (1990). The efficacy of drug therapy in structural lesions of the hair and in diffuse effluvium--comparative double blind study. Schweiz Rundsch Med Prax. 79(47):1457-62. — PubMed PMID: 1709511
  8. Park SY et al. (2013). Iron plays a certain role in patterned hair loss. Journal of Korean Medical Science. 28(6):934-8. — PubMed PMID: 23772161
  9. Trüeb RM (2016). Serum Biotin Levels in Women Complaining of Hair Loss. International Journal of Trichology. 8(2):73-7. — PubMed PMID: 27601860

Back to Table of Contents

Research Papers: Detoxification

  1. Klaassen CD, Liu J, Choudhuri S (1999). Metallothionein: an intracellular protein to protect against cadmium toxicity. Annual Review of Pharmacology and Toxicology. 39:267-94. — PubMed PMID: 10331085
  2. Aposhian HV (1998). Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS). Environmental Health Perspectives. 106(Suppl 4):1017-25. — PubMed PMID: 9703487
  3. Patrick L (2002). Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Alternative Medicine Review. 7(6):456-71. — PubMed PMID: 12495372
  4. Hayes JD, Flanagan JU, Jowsey IR (2005). Glutathione transferases. Annual Review of Pharmacology and Toxicology. 45:51-88. — PubMed PMID: 15822171
  5. Quig D (1998). Cysteine metabolism and metal toxicity. Alternative Medicine Review. 3(4):262-70. — PubMed PMID: 9727078
  6. Flora SJ, Pachauri V (2010). Chelation in metal intoxication. International Journal of Environmental Research and Public Health. 7(7):2745-88. — PubMed PMID: 20717537
  7. Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical Reviews in Biochemistry and Molecular Biology. 30(6):445-600. — PubMed PMID: 8770536
  8. Ballatori N et al. (2009). Glutathione dysregulation and the etiology and progression of human diseases. Biological Chemistry. 390(3):191-214. — PubMed PMID: 19166318
  9. Bernhoft RA (2012). Mercury toxicity and treatment: a review of the literature. Journal of Environmental and Public Health. 2012:460508. — PubMed PMID: 22235210
  10. Pizzorno J (2014). Glutathione! Integrative Medicine. 13(1):8-12. — PubMed PMID: 26770075

Back to Table of Contents

Research Papers: Cross-Cutting (Forms, Status, Safety)

  1. Cazzola M et al. (2015). Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review. 24(137):451-61. — PubMed PMID: 26324807
  2. Cysteine metabolism via the transsulfuration pathway from methionine — PubMed: Transsulfuration
  3. Cysteine sulfinic acid pathway to taurine and sulfate — PubMed: Sulfinic to taurine/sulfate
  4. Cystinuria genetic disorder of cystine reabsorption — PubMed: Cystinuria
  5. Cysteine and zinc interaction in metallothionein induction — PubMed: Zinc/cysteine/MT
  6. GSTM1 and GSTT1 polymorphisms in xenobiotic clearance — PubMed: GST polymorphisms
  7. NAC for psychiatric conditions (OCD, trichotillomania, schizophrenia adjunct) — PubMed: NAC psychiatric
  8. NAC for NAFLD and hepatic glutathione restoration — PubMed: NAC NAFLD
  9. Cysteine availability and the GCL feedback inhibition mechanism — PubMed: GCL regulation

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents